In Stock
Turn to the liposomal amphotericin B agent that can be kinder to the kidneys.
In a clinical study, AmBisome® (amphotericin B) liposome for injection demonstrated a lower incidence of nephrotoxicity than Abelcet®.
Origin
Made in, and imported from the UK
Brand
Active Substance
Liposomal Amphotericin BUses
- Empirical therapy for presumed fungal infection in febrile, neutropenic patients
- Treatment of Cryptococcal Meningitis in HIV-infected patients
- Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate
- Treatment of visceral leishmaniasis
- In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites